Diane Descamps1, Gilles Peytavin2, Benoit Visseaux1, Roland Tubiana3, Florence Damond1, Pauline Campa4, Charlotte Charpentier1, Marie-Aude Khuong-Josses5, Claudine Duvivier6, Marina Karmochkine7, Tuna Lukiana8, Sophie Matheron9. 1. Université Paris Diderot, Sorbonne Paris Cité INSERM, IAME, UMR 1137 Laboratoire de Virologie. 2. Université Paris Diderot, Sorbonne Paris Cité INSERM, IAME, UMR 1137 Laboratoire de Pharmaco-Toxicologie, AP-HP, Hôpital Bichat-Claude Bernard. 3. Service des Maladies Infectieuses et Tropicales, AP-HP, Hôpital Pitié-Salpêtrière Pierre Louis Institute of Epidemiology and Public Health, Sorbonne University, UPMC, INSERM UMR-S1136. 4. Service des Maladies Infectieuses et Tropicales, AP-HP, Hôpital Saint-Antoine, Paris. 5. Service des Maladies Infectieuses et Tropicales, Hôpital Delafontaine, Saint-Denis. 6. Service de Maladies Infectieuses et Tropicales, AP-HP, Hôpital Necker, Centre d'Infectiologie Necker-Pasteur, Université Paris Descartes, Sorbonne Paris Cité IHU Imagine. 7. Service d'Immunologie Clinique, AP-HP, Hôpital Européen Georges Pompidou, Paris. 8. ViiV Healthcare, Marly le Roi. 9. Université Paris Diderot, Sorbonne Paris Cité INSERM, IAME, UMR 1137 Service de Maladies Infectieuses et Tropicales, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France.
Abstract
BACKGROUND: Dolutegravir has shown in vitro activity against human immunodeficiency virus type 2 (HIV-2). We report safety and efficacy data of regimens containing dolutegravir (50 mg twice daily) in antiretroviral-experienced, HIV-2-infected patients. METHODS: HIV-2-infected patients experiencing virological failure to raltegravir received dolutegravir with optimized background antiretroviral combinations within the French Named Patient Program (NPP). Plasma HIV-2 RNA (pVL) was assessed at time of dolutegravir initiation (baseline), month 3, and month 6. Antiretroviral trough plasma concentrations (C12h) were determined using liquid chromatography coupled with tandem mass spectrometry. RESULTS: Thirteen HIV-2-infected-patients, with a median duration of 15 years' infection and given 16 previous antiretroviral regimens, were included in NPP. Median follow-up was 9 months (min-max, 3-15 months). Median baseline pVL and CD4 cell count were 9544 copies/mL (inter quartile range [IQR], 3096-23 120 copies/mL) and 100 cells/µL (IQR, 77-171 cells/µL), respectively. Available integrase genotypic resistance patterns were Y143C/G/H/R (n = 5), Q148R/K (n = 2), and N155H (n = 4). Optimized background antiretroviral regimens conferring a genotypic sensitivity score ≤2 in 10 patients included nucleoside reverse transcriptase inhibitors associated with darunavir/ritonavir (n = 12), saquinavir/ritonavir (n = 2), and maraviroc (n = 3). At months 3 and 6, pVL was undetectable in 6 of 13 and 4 of 12 patients, respectively, and median CD4 count was 161 (101-188) cells/µL and 167 (135-1353) cells/µL, respectively. Median dolutegravir C12h was 4086 (1756-5717 ng/mL) ng/mL in 9 patients. No serious events were notified except 1 death from progressive multifocal leukoencephalopathy at month 4. CONCLUSIONS: Optimized dolutegravir-containing antiretroviral regimens supported by good plasma exposure provide a substantial initial efficacy rate for salvage therapy in heavily antiretroviral-experienced HIV-2-infected patients with virus harboring resistance to first-generation integrase inhibitors. Larger numbers of patients and longer follow-up are needed to confirm these findings.
BACKGROUND:Dolutegravir has shown in vitro activity against human immunodeficiency virus type 2 (HIV-2). We report safety and efficacy data of regimens containing dolutegravir (50 mg twice daily) in antiretroviral-experienced, HIV-2-infectedpatients. METHODS:HIV-2-infectedpatients experiencing virological failure to raltegravir received dolutegravir with optimized background antiretroviral combinations within the French Named Patient Program (NPP). Plasma HIV-2 RNA (pVL) was assessed at time of dolutegravir initiation (baseline), month 3, and month 6. Antiretroviral trough plasma concentrations (C12h) were determined using liquid chromatography coupled with tandem mass spectrometry. RESULTS: Thirteen HIV-2-infected-patients, with a median duration of 15 years' infection and given 16 previous antiretroviral regimens, were included in NPP. Median follow-up was 9 months (min-max, 3-15 months). Median baseline pVL and CD4 cell count were 9544 copies/mL (inter quartile range [IQR], 3096-23 120 copies/mL) and 100 cells/µL (IQR, 77-171 cells/µL), respectively. Available integrase genotypic resistance patterns were Y143C/G/H/R (n = 5), Q148R/K (n = 2), and N155H (n = 4). Optimized background antiretroviral regimens conferring a genotypic sensitivity score ≤2 in 10 patients included nucleoside reverse transcriptase inhibitors associated with darunavir/ritonavir (n = 12), saquinavir/ritonavir (n = 2), and maraviroc (n = 3). At months 3 and 6, pVL was undetectable in 6 of 13 and 4 of 12 patients, respectively, and median CD4 count was 161 (101-188) cells/µL and 167 (135-1353) cells/µL, respectively. Median dolutegravir C12h was 4086 (1756-5717 ng/mL) ng/mL in 9 patients. No serious events were notified except 1 death from progressive multifocal leukoencephalopathy at month 4. CONCLUSIONS: Optimized dolutegravir-containing antiretroviral regimens supported by good plasma exposure provide a substantial initial efficacy rate for salvage therapy in heavily antiretroviral-experienced HIV-2-infectedpatients with virus harboring resistance to first-generation integrase inhibitors. Larger numbers of patients and longer follow-up are needed to confirm these findings.
Authors: Robert A Smith; Dana N Raugi; Vincent H Wu; Christopher G Zavala; Jennifer Song; Khardiata Mbaye Diallo; Moussa Seydi; Geoffrey S Gottlieb Journal: Antimicrob Agents Chemother Date: 2019-04-25 Impact factor: 5.191
Authors: Selly Ba; Dana N Raugi; Robert A Smith; Fatima Sall; Khadim Faye; Stephen E Hawes; Papa Salif Sow; Moussa Seydi; Geoffrey S Gottlieb Journal: Clin Infect Dis Date: 2018-10-30 Impact factor: 9.079
Authors: Robert A Smith; Vincent H Wu; Jennifer Song; Dana N Raugi; Khardiata Diallo Mbaye; Moussa Seydi; Geoffrey S Gottlieb Journal: J Infect Dis Date: 2022-08-26 Impact factor: 7.759
Authors: Philip L Tzou; Diane Descamps; Soo-Yon Rhee; Dana N Raugi; Charlotte Charpentier; Nuno Taveira; Robert A Smith; Vicente Soriano; Carmen de Mendoza; Susan P Holmes; Geoffrey S Gottlieb; Robert W Shafer Journal: J Infect Dis Date: 2020-06-11 Impact factor: 5.226
Authors: Robert A Smith; Vincent H Wu; Christopher G Zavala; Dana N Raugi; Selly Ba; Moussa Seydi; Geoffrey S Gottlieb Journal: Antimicrob Agents Chemother Date: 2018-09-24 Impact factor: 5.191
Authors: Lucia Hans; Nicole von Allmen; Anke Edelmann; Jörg Hofmann; Alex Y Nilsson; Christian O Simon; Britta Seiverth; Peter Gohl; Sergio Carmona Journal: J Acquir Immune Defic Syndr Date: 2021-08-15 Impact factor: 3.771